Relapsing polychondritis, an underestimated dermatological urgency: case report and literature review

No hay miniatura disponible

Fecha

2017

Título de la revista

Publicado en

International Journal of Dermatology, 1365-4632, Vol. 56, No. 12, 2017, p. 1379-1386

Publicado por

Wiley

Enlace a contenidos multimedia

ISSN de la revista

Título del volumen

Resumen

Descripción

Abstract

Relapsing polychondritis is an autoimmune multisystemic disease with primary chondral involvement. Its high mortality and morbidity make it a real clinical challenge. A 32-year-old woman with a history of relapsing polychondritis, refractory to multiple treatments, with multisystem compromise, imminent risk of death due to severe tracheobronchial damage and difficult ventilatory support, and successful treatment with infliximab. Several treatments have been described in the literature, such as nonsteroidal anti-inflammatory drugs, corticosteroids, dapsone, azathioprine, cyclosporine, cyclophosphamide, and methotrexate. However, the cases refractory to conventional therapy may lead to chronicity, irreversibility, and death. As a result, a third-line therapy could improve the prognosis of these patients. Biological therapy is a good option for disease control and quality of life improvement. In addition, the physician should consider these treatments to avoid the chronicity and risk of death of these patients.

Palabras clave

Keywords

Adult, Dermatologic agents, Salvage therapy

Temáticas

Citación

Colecciones